CEO looks to take China Nuokang private after difficult 2011
This article was originally published in Scrip
The Chinese firm China Nuokang Bio-Pharmaceutical has received a preliminary management buyout proposal from its chairman and CEO after slumping to a net loss last year during a challenging business period.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.